01 июля 2002 00:00 |
Serum carcinoembryonic antigen level in surgically resected clinical stage i patients with non-small cell lung cancer
Background. There is little general agreement concerning the effectiveness of serum carcinoembryonic antigen (CEA) as a prognostic indicator for non-small cell lung cancer (NSCLC) in clinical stage I patients. We conducted a retrospective study to investigate the relationship between serum CEA level and survival.
Methods. We assessed 297 consecutive patients with clinical stage I NSCLC who underwent surgical resection at Toneyama National Hospital from 1985 to 1998. Serum CEA levels were measured with an enzyme-linked immunosorbent assay kit with the upper limit of normal defined as 7.0 ng/mL based on the 95% specificity level for benign lung disease, in our hospital.
Results. There were 56 (19%) patients with serum CEA greater than 7.0 ng/mL. The high CEA group had a median survival time of 50 months and a 5−year survival rate of 49% compared with a 5−year survival rate of 72% (p < 0.0001) for the normal CEA group (n = 241). Patients with postoperatively high CEA levels (n = 15) had the worse prognosis (median survival time 35 months, and 5−year survival 18%) compared with patients whose levels returned to normal (n = 41, median survival time 8 8 months, and 5−year survival 68%; p = 0.01). These differences were also observed in patients with pathologic stage I or II tumors but not in those with pathologic stage III or IV tumors.
Conclusions. Serum CEA level is a useful predictor of survival for patients with clinical stage I NSCLC, and a persistently high CEA level after surgery is an especially strong indicator of a very poor prognosis.
Смотри также
01 июля 2002 | 00:07
Fluoroscopy-assisted thoracoscopic resection of lung nodules marked with lipiodol
Background. To localize small and deeply situated pulmonary nodules under thoracoscopy with roentgenographic fluoroscopy, we developed a marking procedure that uses both lipiodol and colored collagen.
20 июня 2002 | 00:06
Генетика рака желудочно-кишечного тракта
Значение проблемы рака желудка и толстой кишки не снижается на протяжении многих лет и становится более острой с ростом заболеваемости. Хотя базовая этиология этих злокачественных опухолей остается
20 июня 2002 | 00:06
Фторафур – первый пероральный фторпиримидин в терапии метастатического колоректального рака
Ежегодно в мире регистрируется около 800 тыс. новых случаев рака толстой и прямой кишки и 440 тыс. смертей от этой болезни [1, 2]. Примерно у 35% пациентов в момент установления диагноза уже
12 июня 2002 | 00:06
The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma
Background. There is evidence that perioperative blood transfusion may lead to immunosuppression. Our aim was to determine whether blood transfusion influenced survival after esophagectomy for
12 июня 2002 | 00:06
Thoracoscopic and laparoscopic lymph node staging in esophageal cancer: do clinicopathological factors affect the outcome?
Background. This study was performed to evaluate the pattern of lymphatic metastases found by combined thoracoscopic (TS) and laparoscopic (LS) lymph node staging in esophageal cancer, and ascertain
